Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
IDT Australia Limited ( (AU:IDT) ) has shared an update.
IDT Australia Limited has announced a strategic realignment to focus on higher-return core business activities, resulting in anticipated annual cost savings of approximately $1 million for FY26. The company is shifting its Specialty Orals vertical towards radiopharmaceuticals, supported by recent contract wins, while maintaining its presence in clinical-stage innovations. Despite a Q1 EBITDA loss of $0.3 million, IDT reported a revenue increase of 18.2% from its three verticals compared to the previous year, driven by strong market demand and new contracts worth $3.4 million. This strategic shift aims to enhance profitability and leverage the company’s operational strengths.
More about IDT Australia Limited
IDT Australia Limited is a pharmaceutical manufacturing company based in Boronia, Victoria, specializing in the development and production of high potency and high containment pharmaceutical products. The company operates with cGMP compliant facilities audited by the US FDA and Australian TGA, offering services in new drug development, scale-up, and manufacture of oral and injectable drug forms.
Average Trading Volume: 307,864
Technical Sentiment Signal: Sell
Current Market Cap: A$24.4M
See more insights into IDT stock on TipRanks’ Stock Analysis page.